A feasibility study of postoperative adjuvant therapy of carboplatin and weekly paclitaxel for completely resected non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 3, Issue 6, 2008, Pages 612-616

  Yamashita, Yoshinori ^a   Kataoka, Kazuhiko ^b   Ishida, Teruyoshi ^c   Matsuura, Motoki ^b   Seno, Noritomo ^b   Mukaida, Hidenori ^a   Miyahara, Eiji ^d   Miyata, Yoshihiro ^e   Okita, Riki ^e   Shimizu, Katsuhiko ^e   Watari, Masanobu ^f   Okumichi, Tsuneo ^g   Okada, Morihito ^f  

^a HIROSHIMA CITY ASA HOSPITAL   (Japan)

^b HIROSHIMA CITY HOSPITAL   (Japan)

^c ATOMIC BOMB SURVIVORS HOSPITAL   (Japan)

^d Saiseikai Hiroshima Hospital   (Japan)

^e HIROSHIMA UNIVERSITY HOSPITAL   (Japan)

^f JA Hiroshima General Hospital

^g Yoshijima Hospital   (Japan)

Author keywords

Adjuvant chemotherapy; Feasibility; Non small cell lung cancer

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALLERGIC REACTION; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG WITHDRAWAL; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAIR LOSS; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEURALGIA; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RASH; STOMATITIS; THROMBOCYTOPENIA;

EID: 44649201145     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e318174e05e     Document Type: Article

References (19)

1. National Comprehensive Cancer Network (NCCN), Clinical Practice Guidelines in Oncology, non-small cell lung cancer, 2007; NSCL-D 1 of 2.
2. Strauss GM, Herndon J, Maddaus MA, et al. Randomozed clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB non-small cell lung cancer (NSCLC), Report of Cancer and Leukemia Group B (CALGB) protocol 9633. J Clin Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement), 2004;7019.
3. Strauss GM, Herndon J, Maddaus MA, et al. Adjuvant chemotherapy in Stage IB non-small cell lung cancer (NSCLC), Update of Cancer and Leukemia Group B (CALGB) protocol 9633. Journal of Clinical Oncology. 2006 ASCO Annual Meeting Proceedings Part I. Vol 24, No. 18S (June 20 Supplement), 2006;7007.
4. Socimski MA, Ivanova A, Bakri K, et al. A randomized phase II trail comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small call lung cancer. Ann Oncol 2006;17:104-109.
5. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
6. Calvert AH, Newell DR, Gumbrel LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;17:1748-1756.
7. Jellifie RW, Jelliffe SM. A computer program for estimation of creatine clearance from unstable serum creatine levels, age, sex and weight. Math Biosci 1972;14:17-24.
8. Hirabayashi M, Endoh K, Teramachi M, et al. Phase II study of carboplatin and weekly paclitaxel combination chemotherapy in advanced non-small lung cancer: a Kansai Clinical Oncology Group study. Lung Cancer 2004;44:355-362.
9. Jodrell DI, Egorin MJ, Conetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol 1992;10:520-528.
10. Chang AY, Rubin J, Asbury R, et al. Weekly paclitaxel in advanced non-small cell lung cancer. Seminars Oncol 2001;28(Suppl 14):40-13.
11. Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with Uracil-Tegafur for adenocarcinoma of the lung. N Eng J Med 2004;350:1713-1721.
12. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.
13. Douillard JY, Rosell R, Lebna MD, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): randomized controlled trial. Lancet Oncol 2006;7:719-727.
14. Rosenberg H, Andersson K, Boman M, et al. A randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated platinum. Acta Oncol 2002;41:418-424.
15. van Warmerdam LJ, Huizing MT, Giaccone G, et al. Clinical pharmacology of carboplatin administered in combination with paclitaxel. Semin Oncol 1997;24(Suppl 2):97-104.
16. Siddiqui N, Boddy AV, Thomas HD, et al. A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer. Br J Cancer 1997;75:287-294.
17. Belani CP, Kearns CM, Zuhowski EG, et al. Phase I trial, including pharmacokinetic and pharmacodynamic correlations of combination of paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999;17:676-684.
18. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Eng J Med 1995;322:1004-1014.
19. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-2939.